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Abstract
Loss of E-cadherin and increased vimentin expression are associated with epithelial-mesenchymal transition and 
cancer stemness which are responsible for treatment resistance. The study aims to evaluate the role of E-cadherin and 
vimentin as predictors of resistance to preoperative systemic therapy in patients with advanced breast cancer. This was 
a cross-sectional analytical study in patients with stage III-IV breast cancer in Dharmais Cancer Hospital and dr. Cipto 
Mangunkusumo National Hospital from July 2015 to April 2016. Patients had biopsy specimens embedded in paraffin 
blocks. Expressions of E-cadherin and vimentin proteins were done immunohistochemically. Treatment response was 
evaluated histopathologically using Miller-Payne criteria on mastectomy specimens. A total of 65 patients were enrolled. 
Five patients with invasive lobular carcinoma were excluded. Thirty one had chemotherapy and 29 had hormonal 
therapy. After treatment, 46 patients were eligible for mastectomy. E-cadherin and vimentin were positive in 28 (60.9%) 
and 11 (20.3%) of specimens. Twenty-three (50%) patients showed no response. Treatment resistance were associated 
with type of therapy (OR=4.4; 95% CI=1.27-15.41; p=0.017) and vimentin expression (OR=6.75; 95% CI=1.27-30.02; 
p=0.016). Hormonal therapy (ORadj=6.26; 95%CI=1.59-24.6; p=0.009) and positive vimentin (ORadj=8.75; 95%CI=1.43-
57.4; p=0.019) were independent predictors of treatment resistance. In conclusion, E-cadherin and vimentin can be 
used as predictors of resistance to preoperative systemic therapy in patients with advanced breast cancer.
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Peran E-cadherin dan Vimentin sebagai Prediktor Resistensi 
Terapi Sistemik Preoperatif pada Pasien Kanker 
Payudara Stadium Lanjut
Abstrak
Hilangnya ekspresi E-cadherin dan meningkatnya ekspresi vimentin dihubungkan dengan epithelial-mesenchymal 
transition dan cancer stemness yang bertanggungjawab terhadap resistensi terapi sistemik preoperatif. Tujuan studi ini 
untuk mengevaluasi peran E-cadherin dan vimentin sebagai prediktor resistensi terapi sistemik preoperatif pada kanker 
payudara stadium lanjut. Studi analitik dengan desain cross sectional ini dilakukan di RS Kanker Dharmais dan RSUPN 
dr. Cipto Mangunkusumo sejak Juli 2015 sampai April 2016. Pasien kanker payudara stadium III-IV dibiopsi dan sampel 
dibuat blok parafin. Ekspresi E-cadherin dan vimentin dianalisis secara imunohistokimia. Respons terapi dievaluasi 
secara histopatologi dengan kriteria Miller-Payne pada pasien yang dilakukan mastektomi. Terdapat 65 pasien namun 
5 pasien karsinoma lobuler dieksklusi. Sebanyak 31 pasien diberikan kemoterapi dan 29 pasien diterapi hormonal; 
setelah terapi, 46 pasien layak mastektomi. E-cadherin dan vimentin positif pada 28 (60,9%) dan 11(20,3%) spesimen. 
Dua puluh tiga (50%) pasien tidak menunjukkan respons terhadap terapi. Resistensi terapi dihubungkan dengan tipe 
terapi (OR=4,4; 95% CI=1,27-15,41; p=0,017) dan ekspresi vimentin (OR=6,75; 95% CI=1,27-30,02; p=0,016). Terapi 
hormonal (ORadj=6,26; 95%CI=1,59-24.6; p=0,009) dan ekspresi vimentin (ORadj=8,75; 95%CI=1,43-57,4; p=0,019) 
adalah prediktor independen resistensi terapi. Disimpulkan E-cadherin dan vimentin dapat berperan sebagai prediktor 
resistensi terapi sistemik preoperatif pada pasien kanker payudara stadium lanjut.
Kata kunci: kanker payudara, cancer stemness, E-cadherin, terapi preoperatif, vimentin
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Introduction
Breast cancer is the most common cancer 
among women worldwide, including Indonesia, and 
accounted for 25% of all new cancers diagnosed 
in 2012.1Advanced stage breast cancer consists 
of locally advanced breast cancer (LABC) or stage 
III and metastatic breast cancer (MBC) or stage 
IV.2,3 These groups of patients are still commonly 
found in Indonesia; 41% and 22% of new cases in 
Dharmais Cancer Hospital were stage III and IV 
disease, respectively.4
Treatment optionsfor advanced stage breast 
cancer are limited and resistance frequently 
occurs.Standard treatment for inoperable, non-
inflammatory LABC is pre-operative chemotherapy 
with anthracylin-based regimen with or without 
taxane.5 Pre-operative systemic treatment in 
inoperable LABC allows breast conserving surgery 
in some patients,6 or alternatively, modified radical 
mastectomy.7 Systemic treatment for MBC could 
prolong survival and improve the patient’s quality 
of life, but not curative. The benefit of mastectomy 
in MBC patients is still controversial. Meta-analysis 
from 10 retrospective studies showed better 3-year 
survival rate (30%) compared to systemic treatment 
alone (22%).8In addition, primary tumor resection 
for MBC patients may give palliative benefits such 
as control of bleeding, ulceration or infection.9
Despite aggressive therapy, some patients 
showed treatment resistance and disease 
progression.10Resistance to treatment might be 
caused by the epithelial-to-mesenchymal transition 
(EMT) process.11,12EMT is a mechanism by which a 
solid tumor acquires metastatic capability. Normal 
breast epithelium expressed epithelial cadherin 
(E-cadherin) that contributes to intercellular junction. 
In advanced stage, epithelial-mesenchymal plasticity 
is increased and cancer cellsmay convert from 
epithelial to mesenchymal phenotype expressing 
vimentin.13,14The EMT process is reversible because 
the mesenchymal cellscan undergo dedifferentiation 
back into epithelial phenotypeand re-expressed 
E-cadherin.15Cancer cells with mesenchymal 
phenotype acquire stem cell characteristics and 
called cancer stem cell (CSC).16 These cells are 
resistant to treatment and may cause disease 
progression.17,18Loss of cell-adhesion proteins (such 
as integrin and E-cadherin) and the emergence of 
vimentin expression are hallmarks of EMT process. 
The final result is increased cell survival and 
resistance to therapy.19,20This study aims to evaluate 
the association of E-cadherin or vimentin expression 
and preoperative systemic treatment response.
Method
Study Design and Subjects
This was an analytical cross-sectional study on 
advanced stage breast cancer patients in Dharmais 
Cancer Hospital and Dr. Cipto Mangunkusumo 
National Hospital from July 2015 to April 2016. 
Patients were included if they had pathologically 
confirmed breast cancer with clinical stage III-IV 
according to TNM system. All patients had biopsy 
specimens before preoperative systemic therapy. 
Patients underwent systemic treatment either with 
chemotherapy or hormonal therapy. Chemotherapy 
regimens consisted of 5-fluorouracil, adriamycin, 
and cyclophosphamide (FAC) given for 6 cycles; 
hormonal therapy were given surgically (bilateral 
salpingo-oophorectomy) or medically using selective 
estrogen receptor modulators (SERMs) or aromatase 
inhibitors (AIs) in hormonal positive receptor patients.
E-cadherin and Vimentin Expressions
Expressions of E-cadherin and vimentin 
proteins were assessed using immuno-
histochemistry staining on paraffin sections of 
biopsy specimens. A 4μm thick section was cut 
and mounted on anobject glass. Antigen retrieval 
and staining was performed with an autostainer 
(Ventana BenchMark GX, Roche). E-cadherin 
staining was done using monoclonal mouse 
anti-E-cadherin/CDH1 antibody (clone 4A2C7, 
TermoFisher Scientific, USA) whereas monoclonal 
rabbit anti-vimentin antibody (RMAB 019 clone 
SP20, DiagnosticBiosystem, USA) was used to 
stain vimentin protein. Slides were left on the tray 
for 30 minutes for antibody incubation. Afterwards, 
slides were washed under running water for 5 
minutes and were dehydrated using ethanol series 
in an increasing concentration, i.e. 70%; 96% and 
absolute ethanol for 5 minutes each. A threshold 
value of 5% was used to define positive expression 
of E-cadherin and vimentin. Slides without specific 
primary antibodies served negative controls.
Evaluation of Treatment Response
Evaluation of treatment response was done 
histopathologically on mastectomy specimens 
using Miller-Payne criteria as follows:21
- Grade 1: no change or some alteration to 
individual malignant cells but no reduction in 
overall cellularity.
- Grade 2: A minor loss of tumor cells but 
overall cellularity still high; up to 30% loss.
- Grade 3: Between an estimated 30% and 
90% reduction in tumor cells.
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- Grade 4: A marked disappearance of tumor 
cells such that only small clusters or widely 
dispersed individual cells remain; more than 
90% loss of tumor cells.
- Grade 5: No malignant cells identifiable 
in sections from the site of the tumor; only 
vascular fibroelastotic stroma remains often 
containing macrophages. Ductal carcinoma 
in situ may be present.
For statistical analysis, treatment response 
were grouped as no response (Miller-Payne grade 
1) and complete or partial response (Miller-Payne 
grade 2-5).
Statistical Analysis
Clinical characteristics of the study subjects 
were presented descriptively as frequency and 
percentage. The association between preoperative 
systemic treatment and clinicopathological variables 
was tested using chi-square of Fisher’s exact 
test. A p value of less than 0.05 was considered 
significant. Logistic regression analyses were 
undertaken to identify the best combination of risk 
factors for treatment resistance. The adjusted odds 
ratio (ORadj) and 95% confidence interval (CI) were 
estimated using the logistic regression coefficient. 
Analyses were performed using statistical software 
(IBV SPSS version 21, SPSS Inc., USA).
Results
A total of 65 patients were enrolled during 
the study period with a mean age of 47.9+10.25 
years. There were 5 cases with invasive lobular 
carcinoma which were excluded from the analysis. 
After treatment, 46 patients were eligible for modified 
radical mastectomy, which included 29/32 (90.6%) 
stage IIIB and 17/28 (60.7%)stage IV patients (Figure 
1). All specimens were evaluated for histopathological 
response; however, only mastectomy specimens 
were included for statistical analysis Table 1).
Figure 1. Study Flow Chart
patients (Figure 1). All specimens were evaluated for histopathological response; 
however, only mastectomy specimens were included for statistical analysis (Table 1).
Figure 1.Study Flow Chart
Table 1.Characteristics of the Study Subjects (n=65)
Variable n %
Age group
<35 years 8 12.3
>35 years 57 87.7
Stage
Stage IIIB 34 52.3
Stage IV 31 47.7
Histopathological type 
Advanced stage breast cancer patients (n=65)
Tumor biopsy 
Preoperative therapy
Chemotherapy for 6 
cycles (n=31)
Hormonal therapy for 
6 months (n=29)
26 mastectomy:
 20 stage IIIB
 6 stage IV
5 biopsy:
 2 stage IIIB
 3 stage IV
20 mastectomy:
 9 stage IIIB
 11 stage IV
9 biopsy:
 1 stage IIIB
 8 stage IV
Evaluation of treatment response
ILC (n=5) IDC 
Excluded
i r  . t  l  rt
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Table 1. Characteristics of the Study Subjects (n=65)
Variables n %
Age group
<35 years 8 12.3
>35 years 57 87.7
Stage
Stage IIIB 34 52.3
Stage IV 31 47.7
Histopathological type 
Invasive ductal carcinoma 60 92.3
Invasive lobular carcinoma 5 7.7
Histopathological grade
Grade 1 11 16.9
Grade 2 29 44.6
Grade 3 25 38.5
Molecular subtypes
Luminal A 41 63.1
Luminal B 11 16.9
HER2-positif 6 9.2
Triple negative 7 10.8
E-cadherin expression
Positive 40 61.5
Negative 25 38.5
Vimentin expression
Positive 18 27.7
Negative 47 72.3
Expression of E-cadherin and Vimentin
Among 46 patients eligible for statistical 
analysis, positive E-cadherin was found in 28 
(60.9%) cases, while positive vimentin expression 
was observed in 11 (23.9%) cases. There was 
neither association between E-cadherin expression 
and clinicopathological factors nor between vimentin 
expression and clinicopathological factors (Table 2).
Variables
E-cadherin Vimentin
Positive Negative p Positive Negative p
Stage
Stage IIIB 18 (62.1%) 11 (37.9%) 0.828* 8 (27.6%) 21 (72.4%) 0.501#
Stage IV 10 (58.5%) 7 (41.2%) 3 (17.6%) 14 (82.4%)
Grade
Grade 1 6 (85.7%) 1 (14.3%) 0.220# 3 (42.9%)  4 (57.1%) 0.333#
Grade 2-3 22 (56.4%) 17 (43.6%) 8 (20.5%) 31 (79.5%)
Subtype
Luminal 20 (55.6%) 16 (44.4%) 0.274# 7 (19.4%) 29 (80.6%) 0.220#
Non-luminal 8 (80.0%) 2 (20.0%) 4 (40.0%) 6 (60.0%)
*Chi-square test; #Fisher’s exact test
Table 2. Association between E-cadherin or Vimentin Expressions and 
Clinicopathological Variables (n=46)
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Evaluation of Treatment Response
Mastectomy specimens were available 
from 46 cases; 23 (50%) among them had no 
response to preoperative therapy. Hormonal 
therapy (OR 4.4) and vimentin expression (OR 
6.75) were significantly associated to more failure 
of preoperative treatment (Table 3). Expression 
of E-cadherin tended to be a protective factor 
towards non-responsive treatment. On multivariate 
analysis (Table 4), hormonal therapy and positive 
vimentin expression were identified as independent 
predictors for non-responsive treatment. 
Table 3. Factors Associated with Response to Preoperative Therapy (n=46)
Variables NR CR/PR p OR 95% CI
Stage
Stage IIIB 15 (51.7%) 14 (48.3%) 0.760* 1.205 0.363-3.998
Stage IV 8 (47.1%) 9 (52.9%)
Grade
Grade 1 6 (85.7%) 1 (14.3%) 0.096# 7.765 0.852-70.752
Grade 2-3 17 (43.6%) 22 (56.4%)
Subtype
Luminal 19 (52.8%) 17 (47.2%) 0.475* 1.676 0.403-6.966
Non-luminal 4 (40.0%) 6 (60.0%)
Preoperative therapy
Hormonal 14 (70.0%) 6 (30.0%) 0.017* 4.407 1.260-15.414
Chemotherapy 9 (34.6%) 17 (65.4%)
E-cadherin
Positive 12 (42.9%) 16 (57.1%) 0.227 0.477 0.143-1.597
Negative 11 (61.1%) 7 (38.9%)
Vimentin
Positive 9 (81.8%) 2 (18.2%) 0.016 6.750 1.265-30.029
Negative 14 (40.0%) 21 (60.0%)
*Chi-square test; #Fisher’s exact test; NR: no response; CR: complete response; PR: partial response 
Table 4. Multivariate Analysis to Predict Treatment Resistance
Variables β SE p ORadj 95% CI
Hormonal therapy 1.73 0.69 0.009 6.26 1.59 – 24.6
Positive vimentin 2.26 0.92 0.019 8.75 1.43 – 57.4
Constant -3.07
SE= standard error; ORadj=adjusted OR; CI: confidence interval 
Discussion
This study was the first comprehensive study 
in Indonesia on advanced stage breast cancer 
patients assessing the expressions of E-cadherin 
and vimentin proteins and their predictive role on 
preoperative treatment response. Despite the 
advanced nature of the disease, less than 40% 
of biopsy specimens in the current study showed 
negative E-cadherin expression, including three 
cases of ILC type. In further analysis, ILC was 
excluded because loss of E-cadherin protein in 
this histopathology type is mostly due to mutation 
of E-cadherin gene promoter, CDH1.22,23However, 
among the rest IDC type, positive E-cadherin 
cells are still high, suggesting intact intracellular 
adhesions and retaining epithelial phenotype of the 
cells.On the other hand, vimentin expression was 
observed in less than 30% patients of all IDC type 
patients. However, positive vimentin expression 
was not corresponded to negative E-cadherin.
Systemic therapy is the mainstay of treatment 
in advanced breast cancer, which includes 
chemotherapy, hormonal (endocrine therapy), 
and targeted therapy.Benefit of neo-adjuvant 
chemotherapy is not limited to down-stage the tumor 
only but also to select next treatment based on 
pathological treatment response and to choose the 
next treatment.24In addition, neo-adjuvant endocrine 
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treatment is a logical option for postmenopausal 
patients with endocrine response (strongly positive 
hormone receptor, low proliferation).25
In this study, patients were given preoperative 
systemic treatment followed by a mastectomy 
whenever clinically possible. More than 90% of 
stage IIIB and 60% of stage IV patients underwent 
mastectomy, giving an overall rate of 76.7% for 
successful down-staging. However, only 50% of 
them showed some degree of histopathological 
response (Miller-Payne grade 2 to 5). Evaluation 
of residual tumor using Miller-Payne criteria was 
based on reduced tumor cellularity between biopsy 
at diagnosis and mastectomy specimens after 
preoperative systemic therapy.21Previous study in 
Pathology Department, dr. Cipto Mangunkusumo 
Hospital, found that 35.7% of 42 LABC patients were 
not responsive to neo-adjuvant chemotherapy.26The 
rate of pathological complete response (pCR) 
varies according to the molecular subtype of breast 
cancer.27,28 Pathological CR is related to better survival 
after neo-adjuvant chemotherapy and surgery.29
Bivariate analysis showed that treatment 
response was significantly associated with type of 
treatment and vimentin expression. Both variables 
consistently showed significant association in 
multivariate analysis. Treatment resistance could be 
predicted by hormonal therapy and positive vimentin.
Resistance to hormonal therapy can occurs 
in all stages, but the most difficult cases are in the 
recurrence setting. Although resistance may exist in 
about half patients before treatment, it alsomay occur 
during treatment.30There are several mechanisms 
involved in hormonal therapy resistance, such as 
mutation of ER gene (ESR1), epigenetic aberration, 
and signaling crosstalk.31ESR1mutation, especially at 
the ligand-binding domain(LBD) site, seems to be the 
major mechanism of resistance related to AI therapy 
in metastatic breast cancer.32,33The resistance may not 
be identified at the time of diagnosis, but it emerges 
due to selective pressure of multiple endocrine 
therapy. Additionally, genetic instability occurring at an 
advanced stage could also contribute to mutation rate, 
for example due to defect of DNA repair mechanisms 
which remain due to the selective pressure.34
Conclusion
A considerably high number of patients 
with advanced stage breast cancer showed 
positive E-cadherin but low vimentin expressions 
(27.7%) suggesting an early process of epithelial-
mesenchymal transition. E-cadherin and vimentin 
can be used as predictors of resistance to 
preoperative systemic therapy in patients with 
advanced breast cancer.
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